Clinical Trial Update: Use of SGLT2i in noHCM With HFpEF [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial is recruiting to evaluate the use of SGLT2 inhibitors in non-obstructive hypertrophic cardiomyopathy with heart failure with preserved …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Hypertrophic Cardiomyopathy

Drugs mentioned

• SGLT2 inhibitors (SGLT2 inhibitor)

Snippet

Sponsor: China National Center for Cardiovascular Diseases | Conditions: Hypertrophic Cardiomyopathy, Heart Failure With Preserved Ejection Fraction | Phase 4 | Status: RECRUITING